Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line panitumumab monotherapy in frail patients with RAS wild-type unresectable colorectal cancer (OGSG 1602)
jRCTs051180108Phase 2Completed
- Sponsor
- Osaka Clinical Study Supporting Organization
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in colorectal cancer (CRC), sponsored by Osaka Clinical Study Supporting Organization. Primary endpoint: Disease control rate. Started Feb 2017; status: completed.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs051180108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180108.